Commure Revenue, Valuation, Funding & Investors

Commure is valued at $7B as of May 2026, a 35.0x multiple on its last reported $200M revenue.

Last Commure valuation

$7B

Undisclosed stage · May 2026

Last Commure funding round

$70M

Undisclosed stage · May 2026

Commure revenue

$200M

Undisclosed stage · May 2026

Key investors in Commure

  • General Catalyst
  • FJ Labs
  • Sequoia Capital
  • Quiet Capital
  • Greenoaks
  • Human Capital

Commure Overview

About Commure

Commure is a San Francisco-headquartered healthcare technology company that delivers an interconnected platform for hospital and health system operations. Its suite of applications includes ambient AI-assisted clinical documentation, revenue cycle automation, staff safety monitoring, and care coordination tools. The platform integrates seamlessly with electronic health record systems through partnerships like the MEDITECH Alliance and enables enterprise-wide AI deployments such as ambient scribing and clinician workflow automation. Commure supports provider networks by offering licensing, implementation services, and content integration to streamline clinical and administrative workflows across large-scale organizations.


Founded

2017

HQ

United StatesSan Francisco, CA

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Revenue

$200M (May 2026)

Valuation

$7B (May 2026)

Commure Valuation

Commure is currently valued at $7B, based on its undisclosed-stage round in May 2026.

The $70M round was led by General Catalyst, with participation from Morgan Stanley Emerg Mkts, Kirkland & Ellis and Sequoia Capital.

Commure's valuation has grown 2.0x from $3.5B at its Series D in September 2021 to $7B in May 2026, across 4 priced rounds.

Commure valuation by funding round

Revenue multiple
Commure valuation by funding round
DateStageValuationRevenue Multiple
May 2026Undisclosed stage$7B35.0x
Oct 2023Undisclosed stage$6B57.1x
Jan 2022Seed$3.5B57.4x
Sep 2021Series D$3.5B33.3x

Commure Revenue

Commure's latest recorded revenue is $200M, as of its undisclosed-stage round in May 2026. At a $7B valuation, that implies a 35.0x revenue multiple.

Revenue grew from $105M in September 2021 to $200M in May 2026, while the revenue multiple moved from 33.3x to 35.0x.

Commure revenue by funding round

Commure revenue and valuation multiple by funding round
DateRevenue *ValuationRevenue MultipleStage
May 2026$200M$7B35.0xUndisclosed stage
Oct 2023$105M$6B57.1xUndisclosed stage
Jan 2022$61M$3.5B57.4xSeed
Sep 2021$105M$3.5B33.3xSeries D

* Revenue (or ARR) figures are the values recorded alongside each funding round. Typically run-rate revenue at the time of the deal, or a reported LTM (last 12 months) revenue.

Commure Funding History

Commure has raised a total of $891M across 10 funding rounds.

Commure's first fundraising round was a $2M seed round in September 2017. The most recent completed round was a $70M undisclosed-stage round in May 2026.

Commure funding rounds

Commure funding rounds
DateStageInvestorsRaisedValuationDeal Summary
May 2026Undisclosed stageGeneral Catalyst (lead); Morgan Stanley Emerg Mkts; Kirkland & Ellis; Sequoia Capital$70M$7BCommure announced $70 million in financing on May 19, 2026 at a $7 billion post-money valuation. The round was led by General Catalyst, with participation from Sequoia Capital, Morgan Stanley, and Kirkland & Ellis. The company previously announced $200 million in growth financing from General Catalyst’s Customer Value Fund in June 2025 to accelerate its AI-powered revenue cycle management platform. The financing was positioned to support continued expansion of Commure’s healthcare operations platform and AI infrastructure for providers. Company materials describe Commure as serving more than 500 healthcare organizations and 3,000+ sites of care, with processing volume across tens of billions in healthcare transactions. The business has raised $750 million to date and has been backed by General Catalyst, Sequoia, Y Combinator, Lux, Human Capital, 8VC, Greenoaks Capital, and Elad Gil. No revenue or EBITDA figures were provided in the available results.
Jun 2025Series EGeneral Catalyst (lead)$200M-Commure is an enterprise AI healthcare technology company providing a full-stack platform spanning revenue cycle management (RCM), ambient AI clinical documentation and workflows, and practice management solutions to healthcare providers. The company serves more than 130 health systems across the United States, powering billions of dollars in annual revenue cycle automations and supporting hundreds of thousands of clinicians. On June 19, 2025, Commure secured $200 million in growth financing from General Catalyst's Customer Value Fund (CVF), a specialized financing vehicle that pre-funds sales and marketing budgets and is repaid through a capped share of revenue from newly acquired customers, allowing the company to scale without equity dilution. Commure reported annual recurring revenue (ARR) of $200 million in live, contracted revenue at the time of the funding announcement, with ARR having doubled for three consecutive years prior. The company serves as a growth platform following its 2023 merger with Athelas at a $6 billion valuation, and CEO Tanay Tandon indicated the company expects to achieve cashflow positivity by mid-to-end 2026 while considering a tender offer and potential public offering within two years of the financing announcement.
May 2024Seed-$5M--
Oct 2023Undisclosed stageGeneral Catalyst (lead)$70M$6BCommure is an AI and software company providing healthcare workflow automation, including revenue cycle management (RCM), ambient AI clinical documentation, and practice management solutions to streamline operations for health systems and providers. Hatched by General Catalyst in 2017 and launched in 2020, Commure merged with Athelas in October 2023, a provider of healthcare workflow automation software, forming a combined entity valued at $6 billion. At that time, Commure received a $70 million investment from General Catalyst as part of the merger. The October 2023 transaction positioned Commure to capture a larger share of the health system market through the merger, with investors including General Catalyst, Human Capital, Greenoaks Capital, 8VC, Lux Capital, and Quiet Capital. Prior to the merger, Commure had raised a $153.75 million Series D in January 2022 at a $3.5 billion valuation. No specific round size, use of funds, or valuation multiples were detailed for the 2023 investment beyond the combined entity valuation. Post-merger traction includes serving over 130 health systems and hundreds of thousands of clinicians, powering billions in annual revenue cycle automations. As of March 2024, estimated ARR reached $105 million, growing 150% YoY. By mid-2025, contracted ARR exceeded $200 million, having doubled for three consecutive years, with paths to profitability noted amid strong demand. In June 2025, Commure secured $200 million growth financing from General Catalyst's Customer Value Fund (CVF), a non-dilutive structure funding sales and marketing repaid via capped customer revenue share, to accelerate product innovation and go-to-market without equity dilution.
Jan 2022Seed-$4M$3.5BCommure develops an AI-powered healthcare software platform that unifies revenue cycle management, clinical workflows, and healthcare operations for providers. The platform integrates ambient AI, revenue cycle automation, clinical documentation tools, and practice management solutions to improve efficiency and reduce administrative burden in hospital systems. On September 16, 2021, Commure raised $250 million in its Series D funding round led by Greenoaks, Human Capital, General Catalyst, and HCA Healthcare at a post-money valuation of $3.5 billion. A follow-on Series D-II round of $3.75 million occurred on January 19, 2022. These rounds supported scaling of the platform and enterprise adoption in the healthcare sector. Commure, headquartered in San Francisco, continued growth with later rounds including a $70 million Series E in October 2023 at a $6 billion valuation for the combined entity after merging with Athelas, and a $200 million growth round in 2025. The company serves over 130 health systems and powers billions in annual revenue cycle automations.
Sep 2021Series DGreenoaks (lead); Human Capital (lead); GBL Capital (lead); Green Sands Equity$500M$3.5BCommure is a health-tech startup providing a data platform and API development tools that enable health systems to build applications in a common technology language, facilitating patient data portability across providers and unlocking ecosystem growth similar to Stripe in payments. Cofounded by Hemant Taneja of General Catalyst, which incubated the company, Commure focuses on integrating with cloud vendors to help providers grow by accessing and utilizing health data more effectively. In September 2021, Commure raised approximately $500 million across two funding rounds, including a $250 million Series D on September 16 led by Greenoaks Capital and Human Capital, with participation from General Catalyst and others like HCA Healthcare. The post-money valuation reached $3.5 billion following the Series D, marking its unicorn status in a cash-flush health-tech sector. Traction included over 20x growth in hospital and health system clients and 40x increase in daily platform transactions in the prior year. The platform supports building new healthcare applications and has been positioned for scalability in data interoperability. Later developments saw additional rounds, such as a $70 million Series E in October 2023 at a $6 billion valuation and a merger with Athelas backed by General Catalyst to form an AI-focused entity valued at $6 billion, planning potential IPO in 2-3 years.
Sep 2020Seed-$3M--
Apr 2019Series BQuiet Capital$27M-Commure is an enterprise AI healthcare technology company developing a full-stack AI platform for providers, including revenue cycle management, ambient AI clinical documentation, workflows, and practice management solutions. The company raised $27 million in a Series B round on April 12, 2019, with investors including Quiet Capital, Accomplice, Andreessen Horowitz, Apollo Projects, Better Tomorrow Ventures, Comma Capital, Correlation Ventures, Diagram Ventures, General Catalyst, Greycroft, Hyperplane Venture Capital, Jean-Denis Greze, John Capodilupo, PJC, Precursor Ventures, Sidharth Kakkar, Tribe Capital, and Village Global. Commure has continued raising capital in subsequent rounds, including Series C rounds in 2020 and 2021 totaling over $350M, multiple Series D rounds from 2021 to 2023 exceeding $250M, Series E in October 2023 for $70M, and a growth round in June 2025 for $200M from General Catalyst's Customer Value Fund, bringing total funding to over $1B across 13 rounds. Recent developments include acquiring Augmedix in July 2024, an AI-enabled clinical documentation provider valued at approximately $134M in the deal.
Jan 2018Series AFJ Labs$10M--
Sep 2017SeedGeneral Catalyst; FJ Labs$2M--

Who has invested in Commure?

10 investors have backed Commure across its funding rounds, including General Catalyst, FJ Labs, Sequoia Capital, Quiet Capital, Greenoaks and Human Capital.

Lead investors include General Catalyst, Greenoaks, Human Capital and GBL Capital.


Commure Investors

Investors in Commure by funding rounds participated
InvestorHQRoundsRoleFirst check
General CatalystUnited StatesSan Francisco, CA4LeadSep 2017
FJ LabsUnited StatesNew York City, NY2ParticipantSep 2017
GreenoaksUnited StatesSan Francisco, CA1LeadSep 2021
Morgan Stanley Emerg MktsUnited StatesUnited States1ParticipantMay 2026
Kirkland & EllisUnited StatesChicago, IL1ParticipantMay 2026
GBL CapitalBelgiumBrussels1LeadSep 2021
Human CapitalUnited StatesSan Francisco, CA1LeadSep 2021
Green Sands EquityUnited StatesSan Francisco, CA1ParticipantSep 2021

This data is available for Pro users. Sign up to see all 10 Commure investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Commure

Commure has acquired 8 companies to date.

Last acquisition by Commure was on December 20th 2024. Commure acquired Memora Health for undisclosed valuation.


Latest Acquisitions by Commure

Memora Health
Augmedix
Rx.Health
Athelas
Description
Memora Health is a San Francisco-headquartered intelligent care enablement platform that automates clinical workflows for health systems and plans. It triages patient-reported data to care team members and enables proactive patient communication via text and voice. Memora partners with organizations such as UCSF Health and Blue Shield of California to streamline care journeys in oncology, cardiology, and maternal health. The platform digitizes intake, symptom monitoring, and follow-up processes to enhance clinician efficiency.
Augmedix is a San Francisco-headquartered ambient AI platform that automates clinical documentation for physicians. Deployed in hospitals and clinics nationwide, it captures patient conversations via smartphones or wearables to generate structured EHR notes, billing codes, and quality measures. Partnering with Mayo Clinic and over 100 health systems, Augmedix processes millions of encounters annually to reduce scribe dependency.
Rx.Health is a New York-based digital medicine platform spun off from Mount Sinai Health System in 2016. The RxUniverse system allows providers to prescribe mobile apps, wearables, educational videos, and therapeutics at the point of care. Deployed across clinical departments like cardiology and oncology, it integrates with electronic health records for over 20 evidence-based digital tools used by thousands of patients annually.
Athelas is a remote patient monitoring company deploying FDA-cleared devices for chronic conditions. San Francisco-headquartered, it tracks blood pressure, weight, glucose, and medication adherence via sensors in homes. Founded in 2015, the platform serves Medicare Advantage plans and integrates with electronic health records for over 10,000 patients.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
San Francisco, CA
San Francisco, CA
New York City, NY
San Francisco, CA
Deal Date20 Dec 202419 Jul 202431 Oct 20234 Oct 2023
Valuationundisclosed$139Mundisclosed$6B
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Commure acquisitions and their M&A valuation multiples.

Start Free Trial

Commure Competitors

Commure competitors include listed companies like Tempus AI and UiPath, and private ones like Abridge, Doctolib, ElevenLabs and Sword Health.

Public and private companies comparable to Commure
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
AbridgeUnited StatesPittsburgh, PAPrivate$117M-$5.3B45.3x
DoctolibFranceParisPrivate$400M-$6.4B16.0x
ElevenLabsPolandWarsawPrivate$500M-$11B22.0x
Sword HealthUnited StatesNew York City, NYPrivate$240M-$4B16.7x
Tempus AIUnited StatesUnited StatesPublicly listed$1.3B($131M)$15B10.1x
UiPathRomaniaRomaniaPublicly listed$1.6B$70M$7.2B3.5x

Commure Public Comps

Commure is still privately-owned, but its public comps include UiPath, M3 Inc., SenseTime Group, Presight AI, Waystar, Doximity, Glaukos, Tenable, CCC Intelligent Solutions and XtalPi.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
UiPath$1.6B$70M3.7x3.5x85.8x13.7x
M3 Inc.$2.3B$473M3.1x3.0x14.8x11.6x
SenseTime Group$748M($70M)6.9x5.8x(73.5x)113.7x
Presight AI$825M$214M6.3x5.4x24.4x20.8x
Waystar$1.1B$390M5.8x5.2x16.3x12.3x
Doximity$645M$229M6.3x6.2x17.7x11.9x
Glaukos$507M($157M)18.4x14.6x(59.6x)166.3x
Tenable$999M$31M4.1x3.9x129.9x15.3x

This data is available for Pro users. Sign up to see all Commure competitors and their valuation data.

Start Free Trial

Common questions about Commure

When was Commure founded?Commure was founded in 2017.
Where is Commure headquartered?Commure is headquartered in San Francisco, CA, United States.
Is Commure publicly listed?No, Commure is a private, VC-backed company.
What is Commure's valuation?Commure was last valued at $7B in its undisclosed-stage round in May 2026.
How much funding has Commure raised?Commure has raised $891M across 10 funding rounds.
What was Commure's last funding round?Commure's last funding round was a $70M undisclosed-stage round in May 2026, led by General Catalyst.
Who are Commure's investors?Commure's investors include General Catalyst, FJ Labs, Greenoaks, Morgan Stanley Emerg Mkts, Kirkland & Ellis, GBL Capital, Human Capital, Green Sands Equity, Sequoia Capital and Quiet Capital.
What is Commure's revenue?Commure's latest recorded revenue is $200M (May 2026).
What is Commure's revenue multiple?Commure's latest valuation implies a 35.0x revenue multiple ($7B valuation on $200M of revenue).
Which companies are comparable to Commure?Companies comparable to Commure include Abridge, Doctolib, ElevenLabs, Sword Health, Tempus AI and UiPath.
How many companies has Commure acquired?Commure has acquired 8 companies, including Memora Health, Augmedix, Rx.Health, Athelas and PatientKeeper.
What was the largest acquisition by Commure?The $6B acquisition of Athelas in October 2023 is the largest acquisition Commure has made to date.

See companies similar to Commure

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial